[Bone marrow autograft treated with mafosfamide in the acceleration phase in chronic myeloid leukemia. Inversion of the clinical development]

Presse Med. 1989 Nov 4;18(36):1785-8.
[Article in French]

Abstract

A 21-year old male patient with Philadelphia chromosome-positive chronic myeloid leukaemia received an autologous bone marrow transplant in consolidation of the 2nd chronic phase. The bone marrow had been treated with mafosfamide in adequate doses. The post-transplantation course of the disease was marked by an inversion: the duration of the 2nd chronic phase was more than 4 times longer than that of the first one, suggesting some degree of effectiveness of autologous bone marrow transplantation performed in the 2nd chronic phase and/for of the in vitro treatment of the bone marrow with mafosfamide. Cytogenetic monitoring was pursued throughout the course of leukaemia: regression of the Philadelphia chromosome was only partial and transient, and 3 clones appeared, each of them involving chromosome 1, for which mafosfamide was most probably responsible.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Adult
  • Antineoplastic Agents / pharmacology*
  • Bone Marrow / drug effects
  • Bone Marrow Transplantation*
  • Chronic Disease
  • Cyclophosphamide / analogs & derivatives*
  • Cyclophosphamide / pharmacology
  • Humans
  • In Vitro Techniques
  • Karyotyping
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / surgery*
  • Male
  • Transplantation, Autologous

Substances

  • Antineoplastic Agents
  • mafosfamide
  • Cyclophosphamide